Skip to main content
CPRX logo
CPRX
(NASDAQ)
Catalyst Pharmaceuticals, Inc.
$24.69-- (--)
Loading... - Market loading

Catalyst Pharmaceuticals (CPRX) Key Statistics & Financial Metrics

Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.

Stock Valuation Metrics

Market value, earnings multiples, and pricing ratios

Market Valuation & Earnings Multiples

Market capitalization, P/E ratios, and enterprise value

Market Cap3.14B
Enterprise Value2.45B
Trailing P/E14.74
Forward P/E11.27

Price-Based Ratios

Valuation ratios based on stock price

Price/Sales (ttm)5.36
Forward Price/Sales4.48
Price/Book (mrq)3.31
Price/Tangible Book (mrq)3.84
Price/FCF (ttm)15.14
Price/OCF (ttm)15.14
PEG Ratio0.48

Enterprise Value Ratios

EV-based valuation multiples

EV/Revenue4.16
EV/Earnings11.44
EV/EBITDA8.03
EV/EBIT9.48
EV/FCF11.75

Stock Price

Current price, 52-week range, and moving averages

Current Price$24.69
1-Day Change0.24%
52-Week High$26.58
52-Week Low$19.05
52-Week Change3.76%
YTD Change7.21%
1-Year Change1.47%
50-Day MA$24.07
200-Day MA$22.22
Avg Volume (30 day)616.05K

Share Statistics

Outstanding shares, float, and per-share metrics

Shares Outstanding127.26M
Book Value per Share$7.50
Net Cash per Share$5.57
FCF per Share$1.64

Analyst Price Targets & Consensus

Wall Street analyst ratings and 12-month price targets (90 days)

Price Target$35.00
Target Upside/Downside41.76%
Analyst ConsensusBuy
Analyst Count1

Profitability & Financial Performance

Profit margins, return metrics, and earnings analysis

Profit Margins

Profitability margins across income statement

Gross Margin87.22%
EBITDA Margin (ttm)51.84%
EBIT Margin (ttm)43.94%
Operating Margin (ttm)43.77%
Pretax Margin (ttm)48.14%
Profit Margin (ttm)36.39%
FCF Margin (ttm)35.42%

Return on Investment Metrics

ROE, ROA, ROIC, and capital efficiency ratios

Return on Equity (ttm)22.46%
Return on Assets (ttm)19.36%
Return on Invested Capital (ttm)78.92%
Return on Capital Employed (ttm)26.97%

Income Statement (TTM)

Trailing twelve months revenue and earnings

Revenue588.99M
Gross Profit513.74M
Operating Income257.78M
Pretax Income283.51M
Net Income214.33M
EBITDA305.33M
EBIT258.77M
Diluted EPS$1.68

Cash Flow (TTM)

Operating cash flow and free cash flow metrics

Operating Cash Flow208.67M
Capital Expenditures58.00K
Free Cash Flow208.61M

Growth Rates (YoY)

Year-over-year growth metrics

Revenue Growth19.78%

Financial Health & Dividends

Balance sheet analysis, debt ratios, and dividend metrics

Assets & Cash

Total assets and cash positions

Total Assets (mrq)1.11B
Cash & Securities (mrq)709.17M
Net Cash (mrq)708.73M
Net Cash per Share$5.57

Debt & Liabilities

Liabilities, debt, equity, and working capital

Total Debt (mrq)2.79M
Working Capital (mrq)746.88M
Total Equity (mrq)954.27M
Book Value per Share$7.50

Liquidity & Leverage

Liquidity, leverage, and debt coverage ratios

Current Ratio (mrq)6.08
Quick Ratio (mrq)5.82
Debt/Equity (mrq)0.00
Debt/EBITDA (ttm)0.01
Debt/FCF (ttm)0.01

Dividend History & Payout Analysis

Dividend yield, payout ratios, and growth metrics

Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%

Yield Metrics

Earnings, FCF, buyback, and shareholder yields

Earnings Yield6.79%
FCF Yield6.60%
Buyback Yield0.80%
Total Shareholder Yield0.80%

Financial Health Scores

Risk assessment and quality metrics

Altman Z-Score15.14
Piotroski F-Score5/9

Fair Value & Intrinsic Value

Lynch fair value, Graham number, and valuation models

Lynch Fair Value$51.72
Lynch Upside/Downside108.38%
Graham Number$16.86
Graham Upside/Downside-32.08%

Frequently Asked Questions About Catalyst Pharmaceuticals Statistics

What are the key financial metrics for CPRX?

Catalyst Pharmaceuticals, Inc. (CPRX) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.

What is CPRX's valuation analysis?

The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Catalyst Pharmaceuticals is overvalued or undervalued.

How do I read CPRX's profitability ratios?

Catalyst Pharmaceuticals's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.

What do CPRX's debt ratios indicate?

The financial health section shows Catalyst Pharmaceuticals's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.

What is CPRX's dividend analysis?

The dividend section covers Catalyst Pharmaceuticals's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.